Intellia Therapeutics, Inc. Net Income Loss

• Intellia Therapeutics, Inc. showed an increase of +20.5% in Net Income Loss from 2024 to 2025.
• This data is from Intellia Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on February 26, 2026.
• XBRL data for this metric is available from 2015 to 2025 (11 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 11 years of available data (2015 to 2025), Intellia Therapeutics, Inc.'s Net Income Loss has declined by 3,229.0%.
• Historical annual values: Fiscal year 2025: -$412.69 million | Fiscal year 2024: -$519.02 million | Fiscal year 2023: -$481.19 million | Fiscal year 2022: -$474.19 million | Fiscal year 2021: -$267.89 million | Fiscal year 2020: -$134.23 million | Fiscal year 2019: -$474.19 million | Fiscal year 2018: -$85.34 million | Fiscal year 2017: -$67.54 million | Fiscal year 2016: -$31.63 million | Fiscal year 2015: -$12.40 million.
• Data sourced from SEC EDGAR public filings as of June 21, 2026.

Last verified: June 21, 2026